Elimination of the antimicrobial action of the organoarsenical cancer therapeutic, 4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid, before finished product sterility testing

Dick, Lindsay J and Gray, Andrew and Ram, Asha and Hume, Aileen and Parris, Caroline and Hogg, Philip J and Elliott, Moira A and Ford, Steven J and Halbert, Gavin W (2013) Elimination of the antimicrobial action of the organoarsenical cancer therapeutic, 4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid, before finished product sterility testing. Journal of Pharmacy and Pharmacology, 65 (11). 1664–1669.

Full text not available in this repository.Request a copy from the Strathclyde author

Abstract

Arsenical compounds have been used therapeutically for over 2000 years finding particular relevance as antimicrobials. After being replaced by more selective and consequently less toxic antibiotics in the last century, arsenicals have recently made a resurgence as anticancer drugs (specifically arsenic trioxide and its derivatives). Arsenical parenteral formulations require post-manufacture sterility testing; however, their intrinsic antimicrobial activity must be neutralised before testing to eliminate the possibility of false (no-growth) test results.